Clinical Trial Update: Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection [Phase 2]

View source ↗

Summary

Durvalumab is being studied in a Phase 2 trial for advanced hepatocellular carcinoma in patients with active chronic hepatitis B infection. The study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING